Open Targets (previously known as Centre for Therapeutic Target Validation, CTTV) aims to provide evidence on the biological validity of therapeutic targets and provide an initial assessment of the likely effectiveness of pharmacological intervention on these targets, using genome-scale experiments and analysis. This open innovation, public-private partnership aims to provide an R&D framework that applies to all aspects of human disease, and to share its data openly with the scientific community. Open Targets brings together complimentary expertise from our five partners, Bristol Myers Squibb, EMBL-EBI, GSK, Wellcome Sanger Institute, and Sanofi. The freely available Open Targets Platform (platform.opentargets.org) makes it easy for researchers working in many disciplines to identify and prioritise therapeutic targets for new medicines. The Platform features over 28,000 targets associated with more than 10,400 diseases, and receives over 1,500 unique visits each week. Read our latest publication: https://europepmc.org/article/MED/33196847 We have also recently released Open Targets Genetics (genetics.opentargets.org), a portal for investigation of Genome Wide Association Study (GWAS) data to assist in identifying the causal genes to prioritise drug targets. The portal aggregates and merges genetic associations curated from literature and newly-derived loci from UK Biobank with (open source) functional genomics data including epigenetics (e.g., chromatin conformation, chromatin interactions) and quantitative trait loci (e.g., eQTLs from GTEX, pQTL), and applies statistical fine-mapping across thousands of trait-associated loci, to resolve association signals and link each variant to its proximal and distal target gene(s), using a single evidence score.